GBM is an aggressive cancer that grows in the cells of the brain or the spinal cord. Credit: April stock via Shutterstock.

Seattle-based device company EMulate Therapeutics has announced that a study proving the effectiveness of its radiofrequency energy device in mouse models of glioblastoma (GBM) has been published. 

The EMulate Therapeutics Voyager devic uses ultra-low radiofrequency energy (ulRFE) to modulate intracellular activity in GBM patients. The investigational device employs silicone over a moulded coil to deliver oscillating magnetic fields, which are thought to interact with and disrupt cellular targets. These fields are derived from the magnetic fluctuations of solvated molecules.  

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Titled “Ultra-Low Radiofrequency Energy (ulRFE) Device in Murine Model of Glioblastoma”, published in the BMC Bioelectronic Medicine journal, the study tested the effectiveness of the emulation of EMulate’s ulRFE signal of paclitaxel, and the immune checkpoint inhibitor ulRFE signal targeting immune checkpoints CTLA-4 and PD-1 in a mouse GBM model. 

Mice injected with glioma cells were treated with one of two ulRFE cognates, A1A, inspired by paclitaxel, a type of chemotherapy, or A2, based on murine siRNA targeting immune checkpoints CTLA4 + PD1. Mice that underwent treatments with either A1A or A2 exhibited significantly reduced tumour sizes when compared to the untreated cohort. 

GBM is an aggressive cancer that grows in the cells of the brain or the spinal cord. GlobalData epidemiologists estimate 79,389 incident cases of GBM in 2023, which are expected to grow to approximately 87,000 cases by 2028. 

See Also:

“EMulate is also seeking to initiate a pivotal Phase III study in newly diagnosed GBM in the future and is also seeking FDA approval for treatment of diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), via the Humanitarian Device Exemption pathway later this year based on encouraging compassionate use results in patients as well as encouraging pre-clinical study results in DIPG animal models,” said its CEO Chris Rivera in the 10 April statement. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The technology is also in pre-clinical testing and initial human testing for use in pain management and central nervous system disorders. 

In April 2023, the US Food and Drug Administration (FDA) granted Breakthrough Device Designation for Innoblative Designs’ SIRA RFA Electrosurgical Device, a radiofrequency energy device designed for use in breast cancer patients undergoing a lumpectomy.